Landmark Research Studies

COMPLETE determined that, on a background of optimal medical therapy with low dose ASA and ticagrelor, a strategy of multi-vessel revascularization, involving staged PCI using drug eluting stents of all suitable non-infarct related artery lesions, was superior to a strategy of culprit lesion-only revascularization in reducing the composite outcome of cardiovascular (CV) death or new MI in patients with multi-vessel disease who have undergone successful culprit lesion primary PCI for STEMI.

Key secondary objectives were:

  • To determine whether complete revascularization reduces the composite of CV death, new MI or ischemia-driven revascularization, and;
  • To determine whether the initial strategy of complete revascularization improves angina control, as assessed by the Seattle Angina Questionnaire (SAQ) Frequency Scale, and health-related quality of life, as assessed by the EQ-5D Quality of Life scale at six months and five year/final follow up compared to baseline.

The findings of the COMPLETE trial received 1A Recommendation and Evidence in the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization

COMPLETE - Download PDF COMPLETE OCT - Download PDF COMPLETE Timing - Download PDF
Study Type

Interventional - Procedure

Study Design

Randomized, prospective, multicenter, open label trial

NO. of Countries


NO. of Sites


NO. of Participants


Study Period




VIDEO: Shamir Meta on COMPLETE trial

VIDEO: David Wood on COMPLETE Timing substudy

VIDEO: Shamir Mehta on COMPLETE analysis on angina-related QoL

VIDEO: Natalia Pinilla Echeverri on COMPLETE OCT substudy

Canadian Institutes of Health Research (CIHR)

Boston Scientific


Back To Top